5-EAPDB
5-EAPDB is the N-ethyl homolog of 5-APDB, a benzofuran entactogen with almost no human characterisation. By analogy to the MDA-to-MDEA relationship, N-ethylation likely yields a milder, more sedating, serotonergic profile. It carries the serotonergic neurotoxicity, hyperthermia, and serotonin-syndrome concerns of the MDMA class.
01 Overview
5-EAPDB sits in the benzofuran entactogen family alongside 5-APB, 5-APDB, and 5-MAPDB. The N-ethyl group typically softens euphoria and increases sedation relative to the primary amine, as seen when comparing MDA and MDEA.
No formal human pharmacology or safety data exist. Its serotonin-releasing action implies neurotoxicity and serotonin-syndrome risk, and benzofurans raise specific 5-HT2B cardiovascular concerns. Likely controlled under benzofuran, analog, or psychoactive-substances provisions.
02 Mechanism
N-ethylated benzofuran serotonin-preferring releaser at monoamine transporters, predicted to give MDMA-like entactogenic effects with a sedating, serotonergic bias.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 60–100 mg | Oral | Estimated; potency poorly defined |
| Common | 100–170 mg | Oral | Estimated common range, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Sedating entactogenesisExpected softer, more sedating MDMA-like effects than 5-APDB by analogy to MDEA. | Presumed moderate | Unconfirmed | |
| Low stimulationN-ethylation predicts reduced stimulation. | Mild | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeTheoretical serious risk from serotonin release, especially in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Cardiovascular strainBenzofurans carry 5-HT2B agonism and cardiovascular load concerns. | Moderate | Common (predicted) | Unconfirmed | |
| HyperthermiaOverheating risk shared with the MDMA class. | Severe | Uncommon | Unconfirmed |